

**To:** Kromhout, J. (Hans)[[h.kromhout@uu.nl](mailto:h.kromhout@uu.nl)]  
**Cc:** Chris Portier[[cportier@mac.com](mailto:cportier@mac.com)]; Isabelle Baldi[[Isabelle.Baldi@isped.u-bordeaux2.fr](mailto:Isabelle.Baldi@isped.u-bordeaux2.fr)]; Aaron Blair[[blaira@exchange.nih.gov](mailto:blaira@exchange.nih.gov)]; GMC24@columbia.edu[[GMC24@columbia.edu](mailto:GMC24@columbia.edu)]; Egeghy, Peter[[Egeghy.Peter@epa.gov](mailto:Egeghy.Peter@epa.gov)]; Forastiere, Francesco[[f.forastiere@deplazio.it](mailto:f.forastiere@deplazio.it)]; Lin Fritschi[[lin.fritschi@curtin.edu.au](mailto:lin.fritschi@curtin.edu.au)]; Jahnke, Gloria (NIH/NIEHS) [E][[jahnke@niehs.nih.gov](mailto:jahnke@niehs.nih.gov)]; Bill Jameson[[drjameson@embarqmail.com](mailto:drjameson@embarqmail.com)]; frank lecurieux[[frank.lecurieux@echa.europa.eu](mailto:frank.lecurieux@echa.europa.eu)]; Martin, Matt[[Martin.Matt@epa.gov](mailto:Martin.Matt@epa.gov)]; John McLaughlin[[John.McLaughlin@oahpp.ca](mailto:John.McLaughlin@oahpp.ca)]; Teresa Rodriguez[[teresar66@gmail.com](mailto:teresar66@gmail.com)]; Matthew Ross[[MRoss@cvm.msstate.edu](mailto:MRoss@cvm.msstate.edu)]; Rusyn, Ivan[[Irusyn@cvm.tamu.edu](mailto:Irusyn@cvm.tamu.edu)]; Mannetje, Andrea[[A.Mannetje@massey.ac.nz](mailto:A.Mannetje@massey.ac.nz)]; Lauren Zeise[[lxzeise@gmail.com](mailto:lxzeise@gmail.com)]; Kate Guyton[[GuytonK@iarc.fr](mailto:GuytonK@iarc.fr)]  
**From:** Consolato Sergi  
**Sent:** Mon 11/9/2015 6:34:12 PM  
**Subject:** Re: IARC Monograph vol 112- EFSA Review of Glyphosate  
[IARCWG112ResponseV2\\_Sergi.docx](#)

Hi Chris,  
I agree with Hans. However, please read my changes (track changes).  
I reviewed the style, because we need to show our academic superior peer-review process, not just arguing, in my opinion and how the process is.  
Please let me know, what you think.  
I would suggest to target Lancet Oncology or Science first  
Another option may be Scientific Reports.  
Best,  
Consolato

On Mon, Nov 9, 2015 at 8:35 AM, Kromhout, J. (Hans) <[h.kromhout@uu.nl](mailto:h.kromhout@uu.nl)> wrote:

Hi Chris,

You did a great job and I'm more than willing to be a co-author of the letter.

Best, Hans

---

From: Chris Portier [[cportier@mac.com](mailto:cportier@mac.com)]  
Sent: Monday, November 09, 2015 12:05 PM  
To: Isabelle Baldi; Aaron Blair; [GMC24@columbia.edu](mailto:GMC24@columbia.edu); Egeghy, Peter; Forastiere, Francesco; Lin Fritschi; Jahnke, Gloria (NIH/NIEHS) [E]; Bill Jameson; Kromhout, J. (Hans); frank lecurieux; Matt Martin; John McLaughlin; Teresa Rodriguez; Matthew Ross; Rusyn, Ivan; Consolato Sergi; Mannetje, Andrea; Lauren Zeise  
Cc: Kate Guyton  
Subject: IARC Monograph vol 112- EFSA Review of Glyphosate

Dear all,

This week, the European Food Safety Agency (EFSA) will release their reassessment of glyphosate. In this review, they will conclude that glyphosate has no carcinogenic potential. This creates two problems as I see it. The first is that this weakens the strength of

the IARC Monograph Program to stimulate change in how some of these agents are reviewed and addressed. The second is that it suggests we did not do our assessment adequately and that, had we seen all of the data they saw, we would have gotten a different answer. I do not intend to let this happen.

The German Federal Institute for Risk Assessment (BfR) was the lead country agency in drafting the reassessment report. This report was drafted prior to the IARC review. In August of this year, following the release of the full Monograph on glyphosate, the BfR drafted an Addendum to their report that specifically addresses the Monograph review. I have decided to draft a letter that I intend to try to get published in Carcinogenesis that addresses the points made by the BfR in their review. Failing my ability to get this into Carcinogenesis, EHP or some other Journal, I intend to send it as an open letter to the European Commission. I am enclosing both the BfR Addendum and my response for you to look over. I would like as many members of the Working Group to be co-authors on this as possible. If you wish to see changes made to the letter I can certainly work on that. If you are uncomfortable signing on to such a letter, I can appreciate that as in my previous job this would have been impossible. Please let me know by Friday November 13 if you can or cannot join me in this endeavor.

Sincerely,

Christopher Portier

--

Consolato Maria Sergi, MSc, MD, PhD, FRCPC

Professor of Pathology and Adj. Professor of Pediatrics

Dept. of Lab. Med. & Pathology (5B4.09), Univ. of Alberta, 8440 112 St, NW, Edmonton, AB, T6G 2B7, Canada

e-mail1: [biotechlab@gmail.com](mailto:biotechlab@gmail.com) / e-mail2: [sergi@ualberta.ca](mailto:sergi@ualberta.ca) / (<http://www.med.ualberta.ca/>)

Tel. +1.780.407.7951 (Office - Direct Line) Tel. +1.780.246.0970 (Cell Phone) / Pager 780.445.1449

Fax. +1.780.407.3009 (U of A Departmental Fax) / **Prof. Networks: LinkedIn, ResearchGate**

WARNING / DISCLAIMER >>> ALL COMMUNICATIONS ARE ENCRYPTED USING HTTPS and this email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the system manager. This message contains confidential information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this e-mail by mistake and delete this e-mail from your system. If you are not the intended recipient you are notified that disclosing, copying, distributing or taking any action in reliance on the contents of this information is strictly prohibited.